ResVir

  • Research type

    Research Study

  • Full title

    Novel technologies for Respiratory Virus identification

  • IRAS ID

    321024

  • Contact name

    Sharon Glaysher

  • Contact email

    sharon.glaysher1@nhs.net

  • Sponsor organisation

    Portsmouth Hospitals University NHS Trust

  • Clinicaltrials.gov Identifier

    NCT05661032

  • Duration of Study in the UK

    1 years, 5 months, 0 days

  • Research summary

    Infectious diseases caused by viruses represent a huge global public health concern, causing many thousands of deaths annually.

    Current virus detection methods often take significant time or can be limited in sensitivity, specificity or cost. There is therefore a need for diagnostic methods that are simple to use, sensitive, rapid and inexpensive.

    This is a proof of concept study to determine whether the OxDx system (a new a rapid pathogen identification technology) is able to detect and differentiate different viruses from nasopharyngeal swabs/aspirate specimens. The data collected will be used to “train” the algorithms to be able to accurately identify respiratory viruses. The accuracy with which the algorithms estimate the test dataset will be monitored at regular intervals during the training dataset collection period. The OxDx system is still under development, which means that it is still “learning”. The system needs to see more information so that it can be sufficiently accurate to be used in clinical practice and should become more accurate in identifying these viruses as it sees more and more information from patients.

    This study will take place at Portsmouth Hospitals University NHS Trust and aims to recruit 1000 patients. To do this, we will recruit both adults and children who either present to the emergency department or are admitted to QAH with a clinical suspicion of a respiratory viral infection. All participants will have a nose and/or throat swab taken as part of their clinical assessment, and we would ask to take a further nasal swab for the purpose of the study. Research sampling will be combined with routine clinical samples where possible to reduce the frequency of testing. We will use most of the information to teach the system how to become more accurate at identifying respiratory viruses. We will keep the remaining information separate and use it to test how accurate the system is. All of the data will be kept securely. Basic information will be collected including age, gender, results of blood tests taken for clinical review, treatment and outcome data. No results from the swabs taken for the purpose of the study will be available to either the participant or the clinical team and the information will have no effect on patient care.

  • REC name

    South Central - Berkshire B Research Ethics Committee

  • REC reference

    22/SC/0467

  • Date of REC Opinion

    17 Jan 2023

  • REC opinion

    Further Information Favourable Opinion